More than 50 years of landmark results
Since 1967, Lowey Dannenberg has represented investors and major corporations in complex litigation, recovering billions of dollars on their behalf.Solutions for Complex Cases
Professional Recommendations
Recent Cases
Shelled Eggs
Antitrust, Commodities
On June 8, Lowey Dannenberg Chairman Vincent Briganti was appointed as Co-Lead Counsel for the Direct Purchaser Plaintiffs in In Re: Shell Eggs Antitrust Litigation, No. 3:26-md-03175-JDP (W.D. Wisc.) Plaintiffs […]
Amitza
Healthcare
Lowey Dannenberg, on behalf of named plaintiff Premera Blue Cross, is leading a class on behalf of Third-Party Payers of Amitiza (Lubiprostone) against Takeda Pharmaceutical Company Ltd. and related entities. […]
Amgen
Health Care, Healthcare
On September 30, 2025, the U.S. District Court for the Eastern District of Virginia largely denied Amgen’s motion to dismiss in CareFirst of Maryland Inc. et al. v. Amgen Inc. […]
News
Lowey Secures $105 Million Recovery for BBSW Investors
On December 10, 2021, Plaintiffs in Dennis, et al. v. JPMorgan Chase & Co., et al., No. 16-cv-06496 (S.D.N.Y.) announced that they entered settlement agreements with Morgan Stanley, Morgan Stanley Australia Limited, Australia and New Zealand Banking Group…
Blog
Rule 10b5-1 Trading Plans Under Scrutiny: Are They Subject To Insider Trading Abuse?
The U.S. Securities and Exchange Commission (SEC) is working to overhaul the rule that protects corporate executives from insider trading accusations when they buy or sell their company’s stocks. Executives are regularly exposed to material nonpublic information (MNPI) and would be at risk of…